11.62
price down icon3.17%   -0.38
after-market アフターアワーズ: 11.62
loading
前日終値:
$12.00
開ける:
$11.88
24時間の取引高:
2.93M
Relative Volume:
0.54
時価総額:
$1.35B
収益:
$52.86M
当期純損益:
$-480.19M
株価収益率:
-2.4777
EPS:
-4.6899
ネットキャッシュフロー:
$-421.82M
1週間 パフォーマンス:
+4.78%
1か月 パフォーマンス:
+1.66%
6か月 パフォーマンス:
+7.00%
1年 パフォーマンス:
+22.19%
1日の値動き範囲:
Value
$11.21
$11.95
1週間の範囲:
Value
$11.21
$12.54
52週間の値動き範囲:
Value
$5.90
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1112)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
598
Name
Twitter
@intelliatweets
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
11.62 1.39B 52.86M -480.19M -421.82M -4.6899
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-12 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-11 ダウングレード Evercore ISI Outperform → In-line
2025-11-07 ダウングレード JP Morgan Neutral → Underweight
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Feb 10, 2026

Will Intellia Therapeutics Inc. stock reach Wall Street targets2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru

Feb 10, 2026
pulisher
Feb 09, 2026

Should you avoid Intellia Therapeutics Inc. stock right nowJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn

Feb 09, 2026
pulisher
Feb 09, 2026

A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Sahm

Feb 09, 2026
pulisher
Feb 09, 2026

Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com

Feb 09, 2026
pulisher
Feb 09, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Feb 09, 2026
pulisher
Feb 07, 2026

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? - AOL.com

Feb 07, 2026
pulisher
Feb 07, 2026

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? - The Motley Fool

Feb 07, 2026
pulisher
Feb 06, 2026

Intellia Therapeutics (NTLA) Awards Inducement Grants to New Emp - GuruFocus

Feb 06, 2026
pulisher
Feb 06, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 06, 2026
pulisher
Feb 06, 2026

Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat

Feb 06, 2026
pulisher
Feb 05, 2026

Best Gene-Editing Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool

Feb 05, 2026
pulisher
Feb 05, 2026

The Best Biotech Stocks to Buy - Morningstar

Feb 05, 2026
pulisher
Feb 05, 2026

Intellia Therapeutics: 2 Major Catalysts Will Determine Stock Trajectory In 2026 (NTLA) - Seeking Alpha

Feb 05, 2026
pulisher
Feb 05, 2026

Notable Two Hundred Day Moving Average CrossNTLA - Nasdaq

Feb 05, 2026
pulisher
Feb 05, 2026

Intellia Therapeutics Receives Key Regulatory Clearance for Clinical Trial - AD HOC NEWS

Feb 05, 2026
pulisher
Feb 04, 2026

Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN

Feb 04, 2026
pulisher
Feb 04, 2026

Intellia Therapeutics (NTLA) Price Target Increased by 35.10% to 23.94 - Nasdaq

Feb 04, 2026
pulisher
Feb 04, 2026

The Technical Signals Behind (NTLA) That Institutions Follow - Stock Traders Daily

Feb 04, 2026
pulisher
Feb 04, 2026

Intellia Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily

Feb 04, 2026
pulisher
Feb 04, 2026

FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang - Sahm

Feb 04, 2026
pulisher
Feb 03, 2026

FDA Lifts Hold On Intellia Trial Refocusing Attention On Valuation Upside - Yahoo Finance

Feb 03, 2026
pulisher
Feb 03, 2026

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Yahoo Finance

Feb 03, 2026
pulisher
Feb 02, 2026

FDA Lifts MAGNITUDE-2 Hold Refocusing Intellia’s ATTR Value Story - Sahm

Feb 02, 2026
pulisher
Feb 02, 2026

Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal - Finviz

Feb 02, 2026
pulisher
Feb 02, 2026

Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal - Insider Monkey

Feb 02, 2026
pulisher
Feb 01, 2026

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail

Feb 01, 2026
pulisher
Feb 01, 2026

The week in pharma: action, reaction and insight – week to January 30, 2026 - The Pharma Letter

Feb 01, 2026
pulisher
Feb 01, 2026

Travel Stocks: Is Intellia Therapeutics Inc a top pick in the sectorRecession Risk & Daily Entry Point Trade Alerts - baoquankhu1.vn

Feb 01, 2026
pulisher
Jan 31, 2026

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial - Sahm

Jan 31, 2026
pulisher
Jan 30, 2026

Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews

Jan 30, 2026
pulisher
Jan 30, 2026

Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis - TipRanks

Jan 30, 2026
pulisher
Jan 30, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail

Jan 30, 2026
pulisher
Jan 30, 2026

Why Intellia Therapeutics (NTLA) Is Down 12.6% After FDA Lifts Hold On Key CRISPR Trial - Sahm

Jan 30, 2026
pulisher
Jan 28, 2026

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials - NeurologyLive

Jan 28, 2026
pulisher
Jan 28, 2026

Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views - Benzinga

Jan 28, 2026
pulisher
Jan 28, 2026

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6%Time to Sell? - MarketBeat

Jan 28, 2026
pulisher
Jan 28, 2026

NTLA Stock Rating Maintained and Price Target Raised by HC Wainw - GuruFocus

Jan 28, 2026
pulisher
Jan 28, 2026

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz

Jan 28, 2026
pulisher
Jan 28, 2026

Y Intercept Hong Kong Ltd Makes New $2.37 Million Investment in Intellia Therapeutics, Inc. $NTLA - MarketBeat

Jan 28, 2026
pulisher
Jan 28, 2026

H.C. Wainwright raises Intellia Therapeutics stock price target on clinical hold lift - Investing.com Canada

Jan 28, 2026
pulisher
Jan 28, 2026

Brokers Offer Predictions for NTLA FY2030 Earnings - MarketBeat

Jan 28, 2026
pulisher
Jan 28, 2026

Intellia Gets Nex-z Phase III Study Boost After FDA Lifts Clinical Hold - Citeline News & Insights

Jan 28, 2026
pulisher
Jan 28, 2026

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance

Jan 28, 2026
pulisher
Jan 28, 2026

Intellia Therapeutics - The Pharma Letter

Jan 28, 2026
pulisher
Jan 28, 2026

FDA Clears MAGNITUDE-2 Hold Leaving Intellia Cardiomyopathy Questions Open - Yahoo Finance

Jan 28, 2026
pulisher
Jan 28, 2026

Intellia Therapeutics to resume dosing of gene therapy in Phase III trial - Clinical Trials Arena

Jan 28, 2026
pulisher
Jan 27, 2026

Intellia gets FDA nod to resume one gene therapy trial after safety pause - ET Pharma

Jan 27, 2026
pulisher
Jan 27, 2026

Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - MSN

Jan 27, 2026
pulisher
Jan 27, 2026

Intellia’s nex-z moves ahead, but only for ATTR-PN for now - BioWorld MedTech

Jan 27, 2026
pulisher
Jan 27, 2026

FDA Lifts Hold on Intellia's Nexiguran Ziclumeran Program (NTLA) - GuruFocus

Jan 27, 2026
pulisher
Jan 27, 2026

Can Intellia Therapeutics Inc. sustain its profitabilityTrend Reversal & Risk Adjusted Buy and Sell Alerts - mfd.ru

Jan 27, 2026

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):